Paraoxonase 1 gene 192 polymorphism, physical activity and lipoprotein in women;Polimorfismo 192 del gen de la paraoxonasa 1, actividad física y lipoproteínas de alta densidad en la mujer

Medicina Clinica

Volumn 122, Issue 4, 2004, Pages 126-129

  Manresaa, Josep Maria ^a   Tomás, Marta ^a   Ribes, Esther ^b   Pi Figueras, Maria ^c   Aguilera, Ana ^c   Sentí, Mariano ^a,d   Marrugat, Jaume ^a,e  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Inst Atencio Geriat Sociosanitaria   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Coronary Disease; Exercise; HDL cholesterol; Lipoproteins; Paraoxonase

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ALLELE; ANTHROPOMETRIC PARAMETERS; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CODON; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DAILY LIFE ACTIVITY; ENZYME ACTIVITY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEART PROTECTION; HOMOZYGOSITY; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; MINNESOTA LEISURE TIME PHYSICAL ACTIVITY QUESTIONNAIRE; PARAOXONASE 1 GENE; PHYSICAL ACTIVITY; PON1 192 GENE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1642289120     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(04)74169-x     Document Type: Article

References (30)

1. Masia R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health 1998;52:707-15.
2. Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatia isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol 2002;55:337-46.
3. Olalla MT, Almazán J, Sierra MJ, Medrano MJ. Mortalidad por enfermedad isquémica del corazón. Bol Epidemiol Semanal 1996;4:213-9.
4. o (NIH) 74-599. Washington DC: US Government Printing Office, 1974.
5. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
6. Weintraub MS, Rosen Y, Otto R, Eisenberg S, Breslow JL. Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 1989;79:1007-14.
7. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 1990; 81:694-6.
8. Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992;85:30-6.
9. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1990;1044:275-83.
10. Codina O, Elosua R, Marrugat J. Actividad fisica y arteriosclerosis. Efectos de la actividad fisica sobre la oxidación lipidica, la hemostasia y la función endotelial. Med Clin (Barc) 1999;112:508-15.
11. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein [published erratum appears in FEBS Lett 1991;292:307]. FEBS Lett 1991;286:152-4.
12. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein [published erratum appears in FEBS Lett 1991;292:307]. FEBS Lett 1991;286:152-4.
13. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
14. Senti M, Tomás M, Elosua R, Sala J, Masia R, Marrugat J. The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study. Clin Chem Lab Med 2002;40:677-83.
15. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995;15:89-95.
16. Senti M, Aubo C, Elosua R, Sala J, Tomás M, Marrugat J. Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg192 variant of the human paraoxonase gene. Genet Epidemiol 2000;18:276-86.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
18. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
19. Elosua R, García M, Aguilar A, Molina L, Covas MI, Marrugat J. Validation of the Minnesota leisure time physical activity questionnaire in Spanish women. Med Sci Sports Exerc 2000;32:1431-7.
20. Tomas M, Sentí M, Elosua R, Vila J, Sala J, Masia R, et al. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol 2001;432:121-8.
21. Sentí M, Aubo C, Elosua R, Sala J, Tomás M, Marrugat J. Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg192 variant of the human paraoxonase gene. Genet Epidemiol 2000;18: 276-86.
22. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999;104:R25-R31.
23. Barboriak JJ, Anderson AJ, Hoffmann RG. Interrelationship between coronary artery occlusion, high-density lipoprotein cholesterol, and alcohol intake. J Lab Clin Med 1979;94:348-53.
24. Fortmann SP, Haskell WL, Williams PT. Changes in plasma high density lipoprotein cholesterol after changes in cigarette use. Am J Epidemiol 1986;124:706-10.
25. Tomás M, Elosua R, Sentí M, Molina L, Vila J, Anglada R, et al. Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonasel activity. J Lipid Res 2002;43:713-20.
26. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26:892-904.
27. Brites FD, Evelson PA, Christiansen MG, Nicol MF, Basilico MJ, Wikinski RW, et al. Soccer players under regular training show oxidative stress but an improved plasma antioxidant status. Clin Sci (Colch) 1999;96:381-5.
28. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11:77-84.
29. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001;276:1923-9.
30. Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR et al. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 2000;20:1946-52.